Home/Pipeline/IBD Flagship Program

IBD Flagship Program

Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)

Discovery/Pre-clinicalActive

Key Facts

Indication
Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
Phase
Discovery/Pre-clinical
Status
Active
Company

About Scailyte

Scailyte is a Basel-based TechBio company building a deep AI foundation model for autoimmune diseases, anchored by a massive single-cell and spatial omics data asset. Its flagship program targets Inflammatory Bowel Disease (IBD), aiming to de-risk drug development, discover novel targets, and create precision diagnostics through advanced patient endotyping. The company operates a partnership-driven business model, offering its platform and insights to pharmaceutical companies to navigate the shift towards high-efficacy precision treatments in immunology.

View full company profile